Zura Bio Completes Approximately $80 Million Financing with

Tibulizumab was licensed from Eli Lilly and Company on April 26, 2023



Total cash and cash equivalents of approximately $120 million is expected to fund planned clinical and operating activities... | June 6, 2023

Related Keywords

, Someit Sidhu , Raymond James , Eli Lilly , Zura Bio , Zura Bio Limited Nasdaq , Exchange Commission , Company Lilly , Zura Bio Limited , Chief Executive Officer , Private Placement Financing , Deep Track Capital , Great Point Partners , Suvretta Capital , Securities Act , Zura Bio Limited Stock Exchange , News , Information , Press Release , Ibulizumab , Gas , Icensed , Rom , Mali , Illy , End , Company , N , Pril , Cash , Equivalents , F , Pproximately , Billion , Us , Xpected , O , Fund , Planned , Linical , Perating Zura Kyg9ty5a1016 ,